Optimer Pharmaceuticals Inc (OPTR)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

101 HUDSON STREET JERSEY CITY, NJ 07302

Optimer Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing anti-infective products primarily to treat gastrointestinal infections and related diseases. Its product candidates include Difimicin (OPT-80), which is in Phase 3 registration trial for the treatment of Clostridium Difficile-associated diarrhea (CDAD), and for the prevention of CDAD; and prevention of nosocomial vancomycin-resistant enterococci bloodstream infections, and methicillin-resistant staphylococci prophylaxis. The company is also developing Prulifloxacin, which is under Phase 3 trial for the treatment of infectious diarrhea, including traveler's diarrhea; OPT-88, a therapy for osteoarthritis; OPT-822/OPT-821, a cancer immunotherapy for the treatment of metastatic breast cancer; and OPT-1068 and OPT-1273 antibiotics for the treatment of upper and lower respiratory tract infections. It has a collaboration agreement with Par Pharmaceutical, Inc. for the clinical development and commercialization of Difimicin; as well as a collaborative research and development, and license agreement with Cempra Pharmaceuticals, Inc. to discover, develop, and commercialize drugs based on macrolide and ketolide compounds.

View SEC Filings from OPTR instead.
Q1 2021 All 13F Filers Prior Change Hedge Funds 1 Prior Change
No data found for this quarter.
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding OPTR (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding OPTR BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

ALTIG ANTHONY E

  • Director
No longer subject to file 2013-10-24 0

CHANG MICHAEL N

  • Director
No longer subject to file 2013-10-24 0

CHANG JOSEPH Y

  • Director
No longer subject to file 2013-10-24 0

AUERBACH MARK

  • Director
No longer subject to file 2013-10-24 0

ZERBE ROBERT L MD

  • Director
No longer subject to file 2013-10-24 0

GREBOW PETER E

  • Director
No longer subject to file 2013-10-24 0

MCKINNELL HENRY A CEO AND CHAIRMAN OF THE BOARD

  • Officer
  • Director
No longer subject to file 2013-10-24 0

AMPER LINDA E SVP, HUMAN RESOURCES

  • Officer
No longer subject to file 2013-10-24 0

GORBACH MD SHERWOOD SVP, CHIEF SCIENTIFIC OFFICER

  • Officer
No longer subject to file 2013-10-24 0

WEBSTER STEPHEN W CHIEF FINANCIAL OFFICER

  • Officer
No longer subject to file 2013-10-24 0

NEWMAN STEPHEN L

  • Director
No longer subject to file 2013-10-24 0

SCHAUM MEREDITH GEN COUNSEL AND CHIEF COMP OFF

  • Officer
No longer subject to file 2013-10-24 0

SIROTA ERIC CHIEF OPERATING OFFICER

  • Officer
No longer subject to file 2013-10-24 0

LICHTINGER PEDRO

  • FORMER CEO
No longer subject to file 2013-04-08 0

HARTMAN KURT M GENERAL COUNSEL, SVP

  • Officer
3,500 2012-08-11 0

PAPAZ GREGORY E. SVP, COMMERCIAL OPERATIONS

  • Officer
2,592 2012-05-15 0

PRUNTY JOHN D CFO AND SVP, FINANCE

  • Officer
0 2012-02-07 0

SHUE YOUE KONG VP, CLINICAL DEVELOPMENT

  • Officer
0 2012-02-07 0

CHE TESSIE M COO AND SVP

  • Officer
821,402 2012-01-01 0

FRAPAISE FRANCOIS-XAVIER CHIEF SCIENTIFIC OFFICER

  • Officer
4,211 2010-11-15 0

POULOS KEVIN P CHIEF COMMERCIAL OFFICER

  • Officer
7,547 2010-05-17 0

SCHREIBER ALAIN

  • Director
0 2010-01-08 0

EDELMAN JOSEPH

PERCEPTIVE ADVISORS LLC

PERCEPTIVE LIFE SCIENCES MASTER FUND LTD

  • 10% Owner
2,654,055 2008-07-02 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments